Lipids and Statin Medication With Sensorineural Hearing Loss: A Mendelian Randomization Study

Abstract

BackgroundRecent insights suggest that lipids and statin medication play a role in the development of sensorineural hearing loss (SNHL), yet the exact role remains controversial. This research applied Mendelian randomization (MR) to assess whether lipids and statin medication are associated with an increased risk of SNHL.MethodsA two‐sample MR was used in this study. Genetic instruments were constructed from variants associated with risk factors. Data for lipids and statin medication were obtained from the IEU OpenGWAS project, and for SNHL from the Finngen research project, which comprises 32,487 individuals with SNHL and 331,736 control individuals.ResultsGenetically predicted higher levels of triglycerides were associated with an increased risk of SNHL. The use of genetically predicted atorvastatin was associated with a lower risk of SNHL. Rosuvastatin has demonstrated potential in treating SNHL, yet further investigations are warranted to elucidate its relationship with SNHL. Insufficient evidence was available to suggest that the genetically predicted level of high‐density lipoprotein cholesterol or low‐density lipoprotein cholesterol or the use of simvastatin were associated with SNHL.ConclusionsThe study provides genetic evidence suggesting that increased levels of triglycerides in the blood could be a risk factor for SNHL and that the use of certain statin medications, including atorvastatin and rosuvastatin, could reduce the risk of SNHL. These results align with findings from previous observational studies that have linked hyperlipidemia with the risk of SNHL.Level of EvidenceAccording to the Oxford Centre for Evidence‐Based Medicine 2011 levels of Evidence, the study has a third level of Evidence Laryngoscope, 2024